A combinatorial inhibition of mTOR and PDGFRB could represent a promising rationale for the treatment of T-ALL patients with low INPP5D expression in the future, since it has been shown that a combinatorial inhibition of the RTK FLT3 and mTOR showed synergistic effects in B-ALL [81]. Here, FLT3 is linked to acute lymphoblastic leukemia.